A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions
Dermatitis, Atopic
Interventions
DRUG

LY3454738

Administered IV

DRUG

LY3454738

Administered SC

DRUG

Placebo

Administered IV

Trial Locations (21)

21225

PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore

27612

Wake Research Associates, Raleigh

33016

Global Health Research Center, Miami Lakes

33122

Revival Research Corporation, Doral

33409

Palm Beach Research Center, West Palm Beach

36207

Pinnacle Research Group, Anniston

40217

Skin Sciences, PLLC, Louisville

46435

Wright State Physicians Dermatology, Dayton

48334

Detroit Clinical Research Center, Farmington Hills

72117

Arkansas Research Trials, LLC, North Little Rock

72758

Northwest Arkansas Clinical Trials Center, Rogers

73071

Central Sooner Research, Norman

77004

Center for Clinical Studies, Houston

78213

Progressive Clinical Research, San Antonio

91206

California Clinical Trials Medical Group, Glendale

92708

First OC Dermatology, Fountain Valley

99202

Premier Clinical Research, Spokane

33613-1244

ForCare Clinical Research, Tampa

10022-3350

JUVA Skin & Laser Center, New York

00727

Dermatology, Los Prados

00917

GCM Medical Group, PSC - Hato Rey Site, San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03750643 - A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter